• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Malignant Lymphoma Market Trends

    ID: MRFR/Pharma/1329-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Malignant Lymphoma Market Research Report Information, by types (Hodgkin lymphoma and Non Hodgkin lymphoma), by treatment (chemotherapy, radiation therapy, immunotherapy, stem cell therapy and others) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Malignant Lymphoma Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Market Trends

    Key Emerging Trends in the Malignant Lymphoma Market

    The market for malignant lymphoma treatment is encountering expanded demand, essentially determined by a developing rate of the infection universally. Factors like maturing populations, environmental factors, and further developed diagnostic capabilities contribute to the rising number of analyzed cases, necessitating effective and different treatment options. Immunotherapy is revolutionizing the scene of malignant lymphoma treatment. Checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and other immunotherapeutic methodologies are showing momentous outcome in certain lymphoma subtypes, giving patients new and targeted treatment options. Pushes in precision medication are molding treatment strategies for malignant lymphoma. Sub-atomic profiling and genetic testing take into consideration a more customized approach, identifying explicit genetic markers and sub-atomic characteristics of the lymphoma to modify treatment plans for individual patients. Pharmaceutical organizations are actively participated in the development of targeted therapies for malignant lymphoma. Targeted agents, for example, monoclonal antibodies and little particle inhibitors, expect to selectively attack cancer cells while limiting harm to healthy tissues, offering more effective and less toxic treatment options. The trend of consolidating different treatment modalities is acquiring noticeable quality in malignant lymphoma treatment. Combinatorial methodologies, which might incorporate chemotherapy, immunotherapy, and targeted therapies, are being investigated to upgrade treatment adequacy, reverse resistance, and work on generally patient outcomes. CAR T-cell therapy is arising as a transformative treatment for certain types of malignant lymphomas. This innovative methodology includes changing a patient's own T cells to target and destroy cancer cells, showing significant achievement, particularly in relapsed or refractory cases. Diagnostic imaging technologies are progressing, supporting early detection and accurate staging of malignant lymphomas. Positron emission tomography-computed tomography (PET-CT) filters and other high level imaging modalities contribute to exact determination, empowering clinicians to tailor treatment plans in view of disease characteristics.

    Market Summary

    As per Market Research Future Analysis, the malignant lymphoma market is projected to reach USD 8,365.4 Million by 2030, growing at a CAGR of 6.7% from 2022 to 2030. Lymphomas, prevalent forms of blood cancer, primarily affect men and are characterized by swollen glands. The market is driven by increasing clinical trials, rising cancer prevalence, and advancements in treatment options. However, high treatment costs and stringent regulations pose challenges. The COVID-19 pandemic has negatively impacted treatment accessibility, but recovery is anticipated as restrictions ease.

    Key Market Trends & Highlights

    Key trends influencing the malignant lymphoma market include advancements in treatment and increasing prevalence.

    • Market expected to reach USD 8,365.4 Million by 2030 at a CAGR of 6.7%;
    • Non-Hodgkin lymphoma predicted to dominate market share due to higher case prevalence;
    • Immunotherapy segment holds significant market share, driven by products like Yescarta;
    • North America accounts for the largest market share due to high prevalence and treatment awareness.

    Market Size & Forecast

    Market Size USD 8,365.4 Million by 2030
    CAGR 6.7% from 2022 to 2030
    Largest Regional Market Share North America.

    Major Players

    Key players include Amgen, Spectrum Pharmaceuticals, Abbott Laboratories, Bristol-Myers Squibb, and Eli Lilly.

    Market Trends

    Drivers:

    Increasing the clinical trials for developing the new drug candidates for various forms of lymphomas specifically for the harder treatment forms is anticipated to accelerate the growth of the market. The growing involvement of major companies in research and development leads to strong pipeline candidates that may propel market growth in the forecast period.

    The rising prevalence of all forms of cancers including other types of blood cancers is one of the key driving factors of the market growth. The disease Lymphoma consists of a few blood cancer cases and there is a rise in demand for advanced products for the treatment. The essential thing was there are no clinical signs for the disease till it is in later stages. At this later stage, a more aggressive form of treatment is required for improved treatment outcomes. This factor is predicted to spur global market growth in the coming years.

    Restraint:

    Expensive treatment, complications related to drugs, low treatment options, and the presence of stringent regulatory guidelines are hampering the market growth.

    Opportunities:

    A rise in the number of improved diagnostic techniques and FDA approvals for therapy drugs may create an opportunity for key players to raise the market growth.

    Challenges:

    Due to the lower lymphoma treatment rates in emerging countries, the cost of the therapies becomes expensive which is reducing the number of individuals undergoing this treatment and most of the patients are not able to afford treatments like immunotherapies. Because the cost of these treatments is not affordable and accessible to poor people.

    Study Objectives

    To provide detailed information about the market structure along with many forecast segments and subsegments for the next 7 years.

    To provide the factors that are impacting the growth of the market value.

     To evaluate the malignant lymphoma market industry analysis based on porter’s five force analysis, factors-price analysis, etc.

    To provide previous and forecast revenue segments and sub-segments of the market revenue for the four main geographies.

    To offer the country-level analysis of the current market size and future prospective. 

    To provide country-level analysis of the global market industry growth by region, type, treatment, and application.

    To provide a strategic profile of the prominent key competitors in the market, analyze their core competencies, and draw a global market growth landscape.

    To track and analyze new product developments, joint ventures, strategic alliances, and global market research.

    The Global Malignant Lymphoma Market is poised for growth, driven by advancements in targeted therapies and an increasing understanding of the disease's molecular underpinnings.

    National Cancer Institute

    Malignant Lymphoma Market Market Drivers

    Rising Incidence of Malignant Lymphoma

    The Global Malignant Lymphoma Market Industry is experiencing growth due to the increasing incidence of malignant lymphoma worldwide. According to health statistics, the prevalence of lymphoma cases has been on the rise, with an estimated 4.37 USD Billion market value in 2024. This surge is attributed to factors such as improved diagnostic techniques and heightened awareness among healthcare professionals and patients. As more individuals are diagnosed, the demand for effective treatment options escalates, thereby driving market expansion. The growing population and aging demographics further contribute to the increase in lymphoma cases, indicating a sustained need for innovative therapies in the Global Malignant Lymphoma Market Industry.

    Market Segment Insights

    Malignant Lymphoma Treatment Insights

    Based on the treatment, the malignant lymphoma market is partitioned into various segments like radiation therapy, chemotherapy, immunotherapy, stem cell therapy, and others. Among them, the immunotherapy segment is holding a significant share due to the higher revenue realization of these drugs. Immunotherapies named Yescarta, a dominant product in this treatment is introduced by Kite Pharma, Inc.

    Get more detailed insights about Malignant Lymphoma Market Research Report- Global Forecast To 2030

    Regional Insights

    Key Companies in the Malignant Lymphoma Market market include

    Industry Developments

    In May 2021, the popular enterpriser PerkinElmer, Inc is planning to acquire the Immunodiagnostic Systems Holdings PLC with an investment of nearly $155 million for expanding their overall diagnostics business.

    In March 2020, one of the well-known companies Kura Oncology conducted a clinical trial for a pipeline candidate named tipifarnib which is used for the disease indication of peripheral T-cell lymphoma. Present, the clinical trial is in Phase-II and it received the fast track designation from the FDA.

    In February 2021, the famous enterpriser Bristol Myers Squibb announced that their company received approval from the U.S Food and Drug Administration (FDA) for cancer immunotherapy as a treatment for adults who are having certain types of non-Hodgkin lymphoma.

    Future Outlook

    Malignant Lymphoma Market Future Outlook

    The Global Malignant Lymphoma Market is projected to grow at a 9.27% CAGR from 2024 to 2035, driven by advancements in targeted therapies and increasing patient awareness.

    New opportunities lie in:

    • Invest in research for novel immunotherapies to enhance treatment efficacy.
    • Develop digital health solutions for patient monitoring and engagement.
    • Expand access to clinical trials in emerging markets to capture new patient demographics.

    By 2035, the market is expected to demonstrate robust growth, reflecting advancements in treatment and increased global awareness.

    Market Segmentation

    Malignant Lymphoma Market Competitive Landscape

    • Abbott Laboratories
    • Actelion Pharmaceuticals
    • Allos Therapeutics
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Genmab
    • Roche
    • Inovio Pharmaceuticals
    • Johnson & Johnson
    • Onyx Pharmaceuticals
    • Seattle Genetics
    • ABIOGEN PHARMA S.P.A
    • Aeterna Zentaris, Inc
    • Astellas Pharma
    • Eli Lilly and Company
    • Merck & Co. Inc
    • Novartis

    Report Scope

    Attribute/Metric Details
      Market Size   8,365.4 Million
      CAGR (2022-2030)   6.7%
      Base Year   2021
      Forecast Period   2022-2030
      Historical Data   2020
      Forecast Units   Value (USD Million)
      Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered  Types and treatment
      Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors  Abbott Laboratories, ABIOGEN PHARMA S.p.A., Actelion Pharmaceuticals, Aeterna Zentaris, Inc., Allos Therapeutics, Astellas Pharma, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genmab, Inovio Pharmaceuticals, Johnson & Johnson, and Merck & Co. Inc., Novartis, Onyx Pharmaceuticals, Roche, Seattle Genetics
      Key Market Opportunities Technological advancement, macro economical and governing factors
      Key Market Drivers Joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    How does the outlook of the global malignant lymphoma market look like?

    The outlook of the global malignant lymphoma market looks very promising.

    What are the major tailwinds pushing the growth of the global malignant lymphoma market?

    Increased government funding for the drug development and increment in the global economy that is widening the access to quality care are the major tailwinds pushing the growth of the global malignant lymphoma market.

    Which region holds the largest share in the global malignant lymphoma market?

    North America holds the largest share in the global malignant lymphoma market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global malignant lymphoma market?

    Abiogen Pharma S.p.A., Abbott Laboratories, Genmab, Actelion Pharmaceuticals, Allos Therapeutics, Aeterna Zentaris, Inc., Novartis, Astellas Pharma, Seattle Genetics Johnson & Johnson, Celgene Corporation, Bristol-Myers Squibb Company, Roche, Merck & Co. Inc., Eli Lilly and Company, Inovio Pharmaceuticals, and Onyx Pharmaceuticals, are some of the major players operating in the malignant lymphoma market.

    What are the key growth strategies of malignant lymphoma industry players?

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global malignant lymphoma market adopt to gain a larger competitive advantage.

    1. TABLE OF CONTENTS
    2. 1          INTRODUCTION           
    3. 1.1        DEFINITION     
    4. 1.2        SCOPE OF STUDY      
    5. 1.2.1     RESEARCH OBJECTIVE          
    6. 1.2.2     ASSUMPTIONS & LIMITATIONS
    7. 1.2.2.1  ASSUMPTIONS
    8. 1.2.2.2  LIMITATIONS    
    9. 1.3        MARKET STRUCTURE:
    10. 2          RESEARCH METHODOLOGY   
    11. 2.1        RESEARCH PROCESS:           
    12. 2.2        PRIMARY RESEARCH 
    13. 2.3        SECONDARY RESEARCH:      
    14. 3          MARKET DYNAMICS   
    15. 3.1        DRIVERS         
    16. 3.2        RESTRAINTS               
    17. 3.3        OPPORTUNITIES         
    18. 3.4        MACROECONOMIC INDICATORS         
    19. 4          MARKET FACTOR ANALYSIS   
    20. 4.1        PORTERS FIVE FORCES MODEL        
    21. 4.2        BARGAINING POWER OF SUPPLIERS 
    22. 4.3        BARGAINING POWER OF BUYERS      
    23. 4.4        THREAT OF NEW ENTRANTS   
    24. 4.5        THREAT OF SUBSTITUTES      
    25. 4.6        INTENSITY OF RIVALRY           
    26. 5       GLOBAL MALIGNANT LYMPHOMA MARKET, BY TYPE
    27. 5.1       HODGKIN LYMPHOMA
    28. 5.2       NON-HODGKIN LYMPHOMA
    29.      GLOBAL MALIGNANT LYMPHOMA MARKET, BY
    30. 6.1       LYMPH NODES
    31. 6.2       BONE MARROW
    32. 6.3       SPLEEN
    33. 6.4       BLOOD
    34. 6.5       OTHER ORGANS
    35. 7.         GLOBAL MALIGNANT LYMPHOMA MARKET, BY DIAGNOSTIC TESTS
    36. 7.1       IMMUNOPHENOTYPING
    37. 7.2       FLUORESCENCE IN SITU HYBRIDIZATION TESTING
    38. 7.3       FLOW CYTOMETER
    39. 8.         GLOBAL MALIGNANT LYMPHOMA MARKET
    40. 8.1       CHEMOTHERAPY
    41. 8.2       RADIATION THERAPY
    42. 8.3       IMMUNOTHERAPY
    43. 8.4       STEM CELL THERAPY
    44. 8.5       OTHERS
    45. 9.         GLOBAL MALIGNANT LYMPHOMA MARKET, BY REGION
    46. 9.1        INTRODUCTION
    47. 9.2        NORTH AMERICA
    48. 9.2.1     US
    49. 9.2.2     CANADA
    50. 9.3        EUROPE
    51. 9.3.1     WESTERN EUROPE
    52. 9.3.1.1  GERMANY
    53. 9.3.1.2  FRANCE
    54. 9.3.1.3  ITALY
    55. 9.3.1.3  SPAIN
    56. 9.3.1.5  UK
    57. 9.3.1.6  REST OF WESTERN EUROPE
    58. 9.3.2     EASTERN EUROPE
    59. 9.4        ASIA
    60. 9.4.1     JAPAN
    61. 9.4.2     CHINA
    62. 9.4.3     INDIA
    63. 9.4.4     AUSTRALIA
    64. 9.4.5     REPUBLIC OF KOREA
    65. 9.4.6     REST OF ASIA-PACIFIC
    66. 9.5        MIDDLE EAST & AFRICA
    67. 9.5.1     UNITED ARAB EMIRATES
    68. 9.5.2     SAUDI ARABIA
    69. 9.5.3     OMAN
    70. 9.5.4     KUWAIT
    71. 9.5.5     QATAR
    72. 9.5.6     REST OF MIDDLE EAST & AFRICA
    73. 10.        COMPETITIVE LANDSCAPE     
    74. 10.1      MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS         
    75. 10.1.1   STRATEGIC PARTNERSHIP     
    76. 10.1.2   MERGER & ACQUISITION        
    77. 11         COMPANY PROFILE    
    78. 11.1      ABBOTT LABORATORIES
    79. 11.1.1   OVERVIEW      
    80. 11.1.2   PRODUCT OVERVIEW 
    81. 11.1.3   FINANCIALS    
    82. 11.1.4   KEY DEVELOPMENTS
    83. 11.2      ABIOGEN PHARMA
    84. 11.2.1   OVERVIEW      
    85. 11.2.2   PRODUCT OVERVIEW 
    86. 11.2.3   FINANCIALS    
    87. 11.2.4   KEY DEVELOPMENTS
    88. 11.3      ACTELION PHARMACEUTICALS
    89. 11.3.1   OVERVIEW
    90. 11.3.2   PRODUCT OVERVIEW 
    91. 11.3.3   FINANCIALS
    92. 11.3.4   STRATEGY      
    93. 11.3.5   KEY DEVELOPMENT   
    94. 11.4      ALLOS THERAPEUTICS
    95. 11.4.1   OVERVIEW
    96. 11.4.2   PRODUCT OVERVIEW
    97. 11.4.3   FINANCIALS
    98. 11.4.4   KEY DEVELOPMENTS
    99. 11.5      BRISTOL-MYERS SQUIBB COMPANY
    100. 11.5.1   OVERVIEW
    101. 11.5.2   PRODUCT OVERVIEW 
    102. 11.5.3   FINANCIALS    
    103. 11.5.4   KEY DEVELOPMENTS
    104. 11.6      OTHERS

    Malignant Lymphoma Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials